 Connection
Nicholas Di bella to Lymphoma, B-Cell
This is a "connection" page, showing publications Nicholas Di bella has written about Lymphoma, B-Cell.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.519 |
|
|
|
-
Di Bella N, Taetle R, Kolibaba K, Boyd T, Raju R, Barrera D, Cochran EW, Dien PY, Lyons R, Schlegel PJ, Vukelja SJ, Boston J, Boehm KA, Wang Y, Asmar L. Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood. 2010 Jan 21; 115(3):475-80.
Score: 0.275
-
Di Bella N, Reynolds C, Faragher D, Muscato J, Boehm KA, Asmar L. An open-label pilot study of pentostatin, mitoxantrone, and rituximab in patients with previously untreated, Stage III or IV, low-grade non-Hodgkin lymphoma. Cancer. 2005 Mar 01; 103(5):978-84.
Score: 0.198
-
Drapkin R, Di Bella NJ, Faragher DC, Harden E, Matei C, Hyman W, Mirabel M, Boehm KA, Asmar L. Results of a phase II multicenter trial of pentostatin and rituximab in patients with low grade B-cell non-Hodgkin's lymphoma: an effective and minimally toxic regimen. Clin Lymphoma. 2003 Dec; 4(3):169-75.
Score: 0.045
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|